Two of the companies are taking a second-go at FDA approval this summer, while another hopes to cement its leader-status in ...

All nine members of the committee unanimously voted to recommend Moderna's new mRNA influenza vaccine for adults 50 and over.

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

Moderna Inc.’s influenza vaccine made with mRNA technology was recommended for approval by outside advisers to the US Food and Drug Administration, a positive development for what has been a ...

By Christy Santhosh and Mariam Sunny June 18 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday backed approval of Moderna's flu vaccine for adults aged 50 and older, saying its ...

Moderna remains a Sell as regulatory setbacks, notably the FDA's Refusal-to-File for mRNA-1010, highlight persistent execution and approval risks. The RTF for mRNA-1010 delays potential influenza ...

The U.S. Food and Drug Administration's advisory panel is set to vote on whether the benefits of Moderna's flu vaccine outweigh its risks in older ‌adults, after regulators reversed course on ...

Your resource for the hottest moving stocks and news. We cover all sectors and markets giving everyday investors access to ...

Moderna said on Wednesday the U.S. drug regulator will review its modified flu vaccine application, a week after rejecting the original submission and fueling industry concerns over shifts in the ...

Two drug companies had a bad week. AstraZeneca (AZN) lost 12.06% last week, while Moderna (MRNA) fell by 14.41%. AZN stock ...